Characterization of the immune environment in pregnancy-associated breast cancer

References

• Lambertini M , BlondeauxE, BruzzoneMet al. Pregnancy after breast cancer: a systematic review and meta-analysis. J. Clin. Oncol.39(29), 3293–3305 (2021).
   PubMed Web of Science ®Google Scholar
• Shao C , YuZ, XiaoJet al. Prognosis of pregnancy-associated breast cancer: a meta-analysis. BMC Cancer20(1), 746 (2020).
   PubMed Web of Science ®Google Scholar
• Chelmow D , PearlmanMD, YoungAet al. Executive summary of the early-onset breast cancer evidence review conference. Obstet. Gynecol.135(6), 1457–1478 (2020).
   PubMed Web of Science ®Google Scholar
• Poggio F , TagliamentoM, PirroneCet al. Update on the management of breast cancer during pregnancy. Cancers (Basel)12(12), 3616 (2020).
   PubMed Web of Science ®Google Scholar
• Blundo C , GirodaM, FuscoNet al. Early breast cancers during pregnancy treated with breast-conserving surgery in the first trimester of gestation: a feasibility study. Front. Oncol.11, 3306 (2021).
   Web of Science ®Google Scholar
• Rees S , YoungA. The experiences and perceptions of women diagnosed with breast cancer during pregnancy. Asia Pac. J. Oncol. Nurs.3(3), 252–258 (2016).
   PubMed Web of Science ®Google Scholar
• Anderson RA , LambertiniM, HallPS, WallaceWH, MorrisonDS, KelseyTW. Survival after breast cancer in women with a subsequent live birth: influence of age at diagnosis and interval to subsequent pregnancy. Eur. J. Cancer173, 113–122 (2022).
   PubMed Web of Science ®Google Scholar
• Amant F , von MinckwitzG, HanSNet al. Prognosis of women with primary breast cancer diagnosed during pregnancy: results from an international collaborative study. J. Clin. Oncol.31(20), 2532–2539 (2013).
   PubMed Web of Science ®Google Scholar
• Loibl S , SchmidtA, GentiliniOet al. Breast cancer diagnosed during pregnancy: adapting recent advances in breast cancer care for pregnant patients. JAMA Oncol.1(8), 1145–1153 (2015).
   PubMed Web of Science ®Google Scholar
• Zagouri F , PsaltopoulouT, DimitrakakisC, BartschR, DimopoulosMA. Challenges in managing breast cancer during pregnancy. J Thorac. Dis.5(Suppl. 1), S62–S67 (2013).
   PubMedGoogle Scholar
• Beadle BM , WoodwardWA, MiddletonLPet al. The impact of pregnancy on breast cancer outcomes in women<or = 35 years. Cancer115(6), 1174–1184 (2009).
   PubMed Web of Science ®Google Scholar
• Rodriguez AO , ChewH, CressRet al. Evidence of poorer survival in pregnancy-associated breast cancer. Obstet. Gynecol.112(1), 71–78 (2008).
   PubMed Web of Science ®Google Scholar
• Murphy CG , MallamD, SteinSet al. Current or recent pregnancy is associated with adverse pathologic features but not impaired survival in early breast cancer. Cancer118(13), 3254–3259 (2012).
   PubMed Web of Science ®Google Scholar
• Baulies S , CusidoM, TresserraFet al. Biological and pathological features in pregnancy-associated breast cancer: a matched case–control study. Eur. J. Gynaecol. Oncol.36(4), 420–423 (2015).
   PubMed Web of Science ®Google Scholar
• Ács B , MadarasL, TőkésAMet al. PD-1, PD-L1 and CTLA-4 in pregnancy-related – and in early-onset breast cancer: a comparative study. Breast35, 69–77 (2017).
   PubMed Web of Science ®Google Scholar
• Nguyen B , VenetD, AzimHAJret al. Breast cancer diagnosed during pregnancy is associated with enrichment of non-silent mutations, mismatch repair deficiency signature and mucin mutations. NPJ Breast Cancer4, 23 (2018).
   PubMed Web of Science ®Google Scholar
• Azim HA Jr , VingianiA, PeccatoriF, VialeG, LoiS, PruneriG. Tumour infiltrating lymphocytes (TILs) in breast cancer during pregnancy. Breast24(3), 290–293 (2015).
   PubMed Web of Science ®Google Scholar
• Azim HA Jr , BroheeS, PeccatoriFAet al. Biology of breast cancer during pregnancy using genomic profiling. Endocr. Relat. Cancer21(4), 545–554 (2014).
   PubMed Web of Science ®Google Scholar
• Sajjadi E , VenetisK, NoaleMet al. Breast cancer during pregnancy as a special type of early-onset breast cancer: analysis of the tumor immune microenvironment and risk profiles. Cells11(15), 2286 (2022).
   PubMed Web of Science ®Google Scholar
• Beaman KD , JaiswalMK, KataraGKet al. Pregnancy is a model for tumors, not transplantation. Am. J. Rep. Immunol.76(1), 3–7 (2016).
   PubMed Web of Science ®Google Scholar
• Korakiti AM , MoutafiM, ZografosE, DimopoulosMA, ZagouriF. The genomic profile of pregnancy-associated breast cancer: a systematic review. Front. Oncol.10, 1773 (2020).
   PubMed Web of Science ®Google Scholar
• Yang F , ZhengQ, JinL. Dynamic function and composition changes of immune cells during normal and pathological pregnancy at the maternal–fetal interface. Front Immunol.10, 2317 (2019).
   PubMed Web of Science ®Google Scholar
• Peterson LS , StelzerIA, TsaiASet al. Multiomic immune clockworks of pregnancy. Semin. Immunopathol.42(4), 397–412 (2020).
   PubMed Web of Science ®Google Scholar
• Bai K , LiX, ZhongJet al. Placenta-derived exosomes as a modulator in maternal immune tolerance during pregnancy. Front. Immunol.12, 671093 (2021).
   PubMed Web of Science ®Google Scholar
• Areia A , Vale-PereiraS, AlvesVet al. Can membrane progesterone receptor α on T regulatory cells explain the ensuing human labour? J. Reprod. Immunol. 113, 22–26 (2016).
   PubMed Web of Science ®Google Scholar
• Piccinni MP , RaghupathyR, SaitoS, Szekeres-BarthoJ. Cytokines, hormones and cellular regulatory mechanisms favoring successful reproduction. Front. Immunol.12, 717808 (2021).
   PubMed Web of Science ®Google Scholar
• Chatterjee P , ChiassonVL, BoundsKR, MitchellBM. Regulation of the anti-inflammatory cytokines interleukin-4 and interleukin-10 during pregnancy. Front. Immunol.5, 253 (2014).
   PubMed Web of Science ®Google Scholar
• Thiele K , HierwegerAM, RiquelmeJIA, SolanoME, LydonJP, ArckPC. Impaired progesterone-responsiveness of CD11c(+) dendritic cells affects the generation of CD4(+) regulatory T cells and is associated with intrauterine growth restriction in mice. Front. Endocrinol. (Lausanne)10, 96 (2019).
   PubMed Web of Science ®Google Scholar
• Mor G , AldoP, AlveroAB. The unique immunological and microbial aspects of pregnancy. Nat. Rev. Immunol.17(8), 469–482 (2017).
   PubMed Web of Science ®Google Scholar
• Mincheva-Nilsson L . Immunosuppressive protein signatures carried by syncytiotrophoblast-derived exosomes and their role in human pregnancy. Front. Immunol.12, 717884 (2021).
   PubMed Web of Science ®Google Scholar
• Atay S , Gercel-TaylorC, SuttlesJ, MorG, TaylorDD. Trophoblast-derived exosomes mediate monocyte recruitment and differentiation. Am. J. Reprod. Immunol.65(1), 65–77 (2011).
   PubMed Web of Science ®Google Scholar
• Salomon C , Scholz-RomeroK, SarkerSet al. Gestational diabetes mellitus is associated with changes in the concentration and bioactivity of placenta-derived exosomes in maternal circulation across gestation. Diabetes65(3), 598–609 (2016).
   PubMed Web of Science ®Google Scholar
• Förger F , VilligerPM. Immunological adaptations in pregnancy that modulate rheumatoid arthritis disease activity. Nat. Rev. Rheumatol.16(2), 113–122 (2020).
   PubMed Web of Science ®Google Scholar
• Kugeratski FG , KalluriR. Exosomes as mediators of immune regulation and immunotherapy in cancer. FEBS J.288(1), 10–35 (2021).
   PubMed Web of Science ®Google Scholar
• Xu L , HuY, LiuW. Tumor microenvironment-mediated immune profiles characterized by distinct survival outcome and immunotherapeutic efficacy in breast cancer. Front. Genet.13, 840348 (2022).
   PubMed Web of Science ®Google Scholar
• Deepak KGK , VempatiR, NagarajuGPet al. Tumor microenvironment: challenges and opportunities in targeting metastasis of triple negative breast cancer. Pharmacol. Res.153, 104683 (2020).
   PubMed Web of Science ®Google Scholar
• Schreiber RD , OldLJ, SmythMJ. Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science331(6024), 1565–1570 (2011).
   PubMed Web of Science ®Google Scholar
• Polyak K . Tumor heterogeneity confounds and illuminates: a case for Darwinian tumor evolution. Nat. Med.20(4), 344–346 (2014).
   PubMed Web of Science ®Google Scholar
• Aguirre-Ghiso JA . Models, mechanisms and clinical evidence for cancer dormancy. Nat. Rev. Cancer.7(11), 834–846 (2007).
   PubMed Web of Science ®Google Scholar
• Riaz N , HavelJJ, MakarovVet al. Tumor and microenvironment evolution during immunotherapy with nivolumab. Cell171(4), 934–49.e16 (2017).
   PubMed Web of Science ®Google Scholar
• Mittal D , GubinMM, SchreiberRD, SmythMJ. New insights into cancer immunoediting and its three component phases – elimination, equilibrium and escape. Curr. Opin. Immunol.27, 16–25 (2014).
   PubMed Web of Science ®Google Scholar
• Teng MW , GalonJ, FridmanWH, SmythMJ. From mice to humans: developments in cancer immunoediting. J. Clin. Invest.125(9), 3338–3346 (2015).
   PubMed Web of Science ®Google Scholar
• Salemme V , CentonzeG, CavalloF, DefilippiP, ContiL. The crosstalk between tumor cells and the immune microenvironment in breast cancer: implications for immunotherapy. Front. Oncol.11, 610303 (2021).
   PubMed Web of Science ®Google Scholar
• Gatti-Mays ME , BalkoJM, GameiroSRet al. If we build it they will come: targeting the immune response to breast cancer. NPJ Breast Cancer5, 37 (2019).
   PubMed Web of Science ®Google Scholar
• Lorenzo-Sanz L , MuñozP. Tumor-infiltrating immunosuppressive cells in cancer-cell plasticity, tumor progression and therapy response. Cancer Microenviron.12(2–3), 119–132 (2019).
   PubMed Web of Science ®Google Scholar
• Sajjadi E , GaudiosoG, TerrasiAet al. Osteoclast-like stromal giant cells in breast cancer likely belong to the spectrum of immunosuppressive tumor-associated macrophages. Front. Mol. Biosci.9, 894247 (2022).
   PubMed Web of Science ®Google Scholar
• Giraldo NA , Sanchez-SalasR, PeskeJDet al. The clinical role of the TME in solid cancer. Br. J. Cancer120(1), 45–53 (2019).
   PubMed Web of Science ®Google Scholar
• Rooney MS , ShuklaSA, WuCJ, GetzG, HacohenN. Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell160(1–2), 48–61 (2015).
   PubMed Web of Science ®Google Scholar
• Fusco N , VairaV, RighiIet al. Characterization of the immune microenvironment in malignant pleural mesothelioma reveals prognostic subgroups of patients. Lung Cancer150, 53–61 (2020).
   PubMed Web of Science ®Google Scholar
• Esposito A , MarraA, BagnardiVet al. Body mass index, adiposity and tumour infiltrating lymphocytes as prognostic biomarkers in patients treated with immunotherapy: a multi-parametric analysis. Eur. J. Cancer145, 197–209 (2021).
   PubMed Web of Science ®Google Scholar
• Criscitiello C , Guerini-RoccoE, VialeGet al. Immunotherapy in breast cancer patients: a focus on the use of the currently available biomarkers in oncology. Anticancer Agents Med. Chem.22(4), 787–800 (2022).
   PubMed Web of Science ®Google Scholar
• El Bairi K , HaynesHR, BlackleyEet al. The tale of TILs in breast cancer: a report from The International Immuno-Oncology Biomarker Working Group. NPJ Breast Cancer7(1), 150 (2021).
   PubMed Web of Science ®Google Scholar
• Salgado R , DenkertC, DemariaSet al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann. Oncol.26(2), 259–271 (2015).
   PubMed Web of Science ®Google Scholar
• Dieci MV , MathieuMC, GuarneriVet al. Prognostic and predictive value of tumor-infiltrating lymphocytes in two phase III randomized adjuvant breast cancer trials. Ann. Oncol.26(8), 1698–1704 (2015).
   PubMed Web of Science ®Google Scholar
• Adams S , GrayRJ, DemariaSet al. Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J. Clin. Oncol.32(27), 2959–2966 (2014).
   PubMed Web of Science ®Google Scholar
• Liu Z , LiM, JiangZ, WangX. A comprehensive immunologic portrait of triple-negative breast cancer. Transl Oncol.11(2), 311–329 (2018).
   PubMed Web of Science ®Google Scholar
• Jagtap SV . Evaluation of CD4+ T-cells and CD8+ T-cells in triple-negative invasive breast cancer. Indian J. Pathol. Microbiol.61(4), 477–478 (2018).
   PubMed Web of Science ®Google Scholar
• Byrne A , SavasP, SantSet al. Tissue-resident memory T cells in breast cancer control and immunotherapy responses. Nat. Rev. Clin. Oncol.17(6), 341–348 (2020).
   PubMed Web of Science ®Google Scholar
• Ingold Heppner B , UntchM, DenkertCet al. Tumor-infiltrating lymphocytes: a predictive and prognostic biomarker in neoadjuvant-treated HER2-positive breast cancer. Clin Cancer Res.22(23), 5747–5754 (2016).
   PubMed Web of Science ®Google Scholar
• Perez EA , BallmanKV, TennerKSet al. Association of stromal tumor-infiltrating lymphocytes with recurrence-free survival in the N9831 adjuvant trial in patients with early-stage HER2-positive breast cancer. JAMA Oncol.2(1), 56–64 (2016).
   PubMed Web of Science ®Google Scholar
• Kossai M , Radosevic-RobinN, Penault-LlorcaF. Refining patient selection for breast cancer immunotherapy: beyond PD-L1. ESMO Open6(5), 100257 (2021).
   PubMed Web of Science ®Google Scholar
• Kornepati AVR , VadlamudiRK, CurielTJ. Programmed death ligand 1 signals in cancer cells. Nat. Rev. Cancer22(3), 174–189 (2022).
   PubMed Web of Science ®Google Scholar
• Matikas A , ZerdesI, LövrotJet al. Prognostic implications of PD-L1 expression in breast cancer: systematic review and meta-analysis of immunohistochemistry and pooled analysis of transcriptomic data. Clin. Cancer Res.25(18), 5717–5726 (2019).
   PubMed Web of Science ®Google Scholar
• Hanamura T , KitanoS, KagamuHet al. Immunological profiles of the breast cancer microenvironment represented by tumor-infiltrating lymphocytes and PD-L1 expression. Sci. Rep.12(1), 8098 (2022).
   PubMed Web of Science ®Google Scholar
• Zhang M , SunH, ZhaoS, WangY, PuH, ZhangQ. Expression of PD-L1 and prognosis in breast cancer: a meta-analysis. Oncotarget8(19), 31347–31354 (2017).
   PubMedGoogle Scholar
• Jiang X , WangJ, DengXet al. Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape. Mol. Cancer18(1), 10 (2019).
   PubMed Web of Science ®Google Scholar
• Alexandrov LB , Nik-ZainalS, WedgeDCet al. Signatures of mutational processes in human cancer. Nature500(7463), 415–421 (2013).
   PubMed Web of Science ®Google Scholar
• Piciotti R , VenetisK, SajjadiE, FuscoN. Mismatch repair status characterization in oncologic pathology: taking stock of the real-world possibilities. J. Molecular Pathology2(2), 93–100 (2021).
   Google Scholar
• Dal Buono A , GaianiF, PolianiL, CorrealeC, LaghiL. Defects in MMR genes as a seminal example of personalized medicine: from diagnosis to therapy. J. Pers.Med.11(12), 1333 (2021).
   PubMed Web of Science ®Google Scholar
• Fusco N , LopezG, CortiCet al. Mismatch repair protein loss as a prognostic and predictive biomarker in breast cancers regardless of microsatellite instability. JNCI Cancer Spectr.2(4), pky056 (2018).
   PubMedGoogle Scholar
• Corti C , SajjadiE, FuscoN. Determination of mismatch repair status in human cancer and its clinical significance: does one size fit all?Adv. Anat. Pathol.26(4), 270–279 (2019).
   PubMed Web of Science ®Google Scholar
• Lopez G , FuscoN. RE: mismatch repair protein loss in breast cancer: clinicopathological associations in a large British Columbia cohort. Breast Cancer Res. Treat.180(1), 265–266 (2020).
   PubMed Web of Science ®Google Scholar
• Cheng AS , LeungSCY, GaoDet al. Mismatch repair protein loss in breast cancer: clinicopathological associations in a large British Columbia cohort. Breast Cancer Res. Treat.179, 3–10 (2020).
   PubMed Web of Science ®Google Scholar
• Zehir A , BenayedR, ShahRHet al. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10.000 patients. Nat. Med.23(6), 703–713 (2017).
   PubMed Web of Science ®Google Scholar
• Sha D , JinZ, BudcziesJ, KluckK, StenzingerA, SinicropeFA. Tumor mutational burden as a predictive biomarker in solid tumors. Cancer Discov.10(12), 1808–1825 (2020).
   PubMed Web of Science ®Google Scholar
• Provenzano E , ShaabanAM. Pathology of neoadjuvant therapy and immunotherapy testing for breast cancer. Histopathology82(1), 170–188 (2023).
   PubMed Web of Science ®Google Scholar
• Chic N , Brasó-MaristanyF, PratA. Biomarkers of immunotherapy response in breast cancer beyond PD-L1. Breast Cancer Res. Treat.191(1), 39–49 (2022).
   PubMed Web of Science ®Google Scholar
• Chan TA , YarchoanM, JaffeeEet al. Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic. Ann. Oncol.30(1), 44–56 (2019).
   PubMed Web of Science ®Google Scholar
• Mei P , FreitagCE, WeiL, ZhangY, ParwaniAV, LiZ. High tumor mutation burden is associated with DNA damage repair gene mutation in breast carcinomas. Diagn. Pathol.15(1), 50 (2020).
   PubMed Web of Science ®Google Scholar
• Merino DM , McShaneL, ButlerMet al. TMB standardization by alignment to reference standards: phase II of the Friends of Cancer Research TMB Harmonization Project. J. Clin. Oncol.37(Suppl. 15), 2624 (2019).
   Web of Science ®Google Scholar
• Karn T , DenkertC, WeberKEet al. Tumor mutational burden and immune infiltration as independent predictors of response to neoadjuvant immune checkpoint inhibition in early TNBC in GeparNuevo. Ann. Oncol.31(9), 1216–1222 (2020).
   PubMed Web of Science ®Google Scholar
• Karn T , JiangT, HatzisCet al. Association between genomic metrics and immune infiltration in triple-negative breast cancer. JAMA Oncol.3(12), 1707–1711 (2017).
   PubMed Web of Science ®Google Scholar
• Barrett MT , LenkiewiczE, MalasiSet al. The association of genomic lesions and PD-1/PD-L1 expression in resected triple-negative breast cancers. Breast Cancer Res.20(1), 71 (2018).
   PubMedGoogle Scholar
• Bayraktar S , BatooS, OkunoS, GlückS. Immunotherapy in breast cancer. J. Carcinog.18, 2 (2019).
   PubMedGoogle Scholar
• Zacharakis N , HuqLM, SeitterSJet al. Breast cancers are immunogenic: immunologic analyses and a phase II pilot clinical trial using mutation-reactive autologous lymphocytes. J. Clin. Oncol.40(16), 1741–1754 (2022).
   PubMed Web of Science ®Google Scholar
• Fusco N , SajjadiE, VenetisKet al. Low-risk triple-negative breast cancers: clinico-pathological and molecular features. Crit. Rev. Oncol. Hematol.172, 103643 (2022).
   PubMed Web of Science ®Google Scholar
• Loi S , MichielsS, SalgadoRet al. Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. Ann. Oncol.25(8), 1544–1550 (2014).
   PubMed Web of Science ®Google Scholar
• Loi S , DrubayD, AdamsSet al. Tumor-infiltrating lymphocytes and prognosis: a pooled individual patient analysis of early-stage triple-negative breast cancers. J. Clin. Oncol.37(7), 559–569 (2019).
   PubMed Web of Science ®Google Scholar
• Burstein HJ , CuriglianoG, LoiblSet al. Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019. Ann. Oncol.30(10), 1541–1557 (2019).
   PubMed Web of Science ®Google Scholar
• Corso G , D’EcclesiisO, MagnoniFet al. Metaplastic breast cancers and triple-negative breast cancers of no special type: are they prognostically different? A systematic review and meta-analysis. Eur. J. Cancer Prev.31(5), 459–466 (2022).
   PubMed Web of Science ®Google Scholar
• Loi S , AdamsS, SchmidPet al. Relationship between tumor infiltrating lymphocyte (TIL) levels and response to pembrolizumab (pembro) in metastatic triple-negative breast cancer (mTNBC): results from KEYNOTE-086. Ann. Oncol.28, v608 (2017).
   Web of Science ®Google Scholar
• Adams S , SchmidP, RugoHSet al. Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study. Ann. Oncol.30(3), 397–404 (2019).
   PubMed Web of Science ®Google Scholar
• Loi S , Giobbie-HurderA, GombosAet al. Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b–2 trial. Lancet Oncol.20(3), 371–382 (2019).
   PubMed Web of Science ®Google Scholar
• Gao ZH , LiCX, LiuM, JiangJY. Predictive and prognostic role of tumour-infiltrating lymphocytes in breast cancer patients with different molecular subtypes: a meta-analysis. BMC Cancer20(1), 1150 (2020).
   PubMed Web of Science ®Google Scholar
• Patsoukis N , WangQ, StraussL, BoussiotisVA. Revisiting the PD-1 pathway. Sci. Adv.6(38), 2712 (2020).
   Web of Science ®Google Scholar
• Litvin IE , PaganellaMP, WendlandEM, RoeheAV. Prognosis of PD-L1 in human breast cancer: protocol for a systematic review and meta-analysis. Syst. Rev.9(1), 66 (2020).
   PubMedGoogle Scholar
• Han Y , LiuD, LiL. PD-1/PD-L1 pathway: current researches in cancer. Am. J. Cancer Res.10(3), 727–742 (2020).
   PubMed Web of Science ®Google Scholar
• Tokumaru Y , JoyceD, TakabeK. Current status and limitations of immunotherapy for breast cancer. Surgery167(3), 628–630 (2020).
   PubMed Web of Science ®Google Scholar
• Emens LA , AdamsS, BarriosCHet al. LBA16 IMpassion130: final OS analysis from the pivotal phase III study of atezolizumab+nab-paclitaxel vs placebo+nab-paclitaxel in previously untreated locally advanced or metastatic triple-negative breast cancer. Ann. Oncol.31, S1148 (2020).
   PubMed Web of Science ®Google Scholar
• Araujo-Fernandez I , DelgadoJ, MoscettiLet al. The European Medicines Agency review of the initial application of atezolizumab and the role of PD-L1 expression as biomarker for checkpoint inhibitors. ESMO Open6(1), 100008 (2021).
   PubMed Web of Science ®Google Scholar
• Roche . Roche provides update on Tecentriq US indication for PD-L1-positive, metastatic triple-negative breast cancer. Press release (2021). https://www.globenewswire.com/news-release/2021/08/27/2287799/0/en/Roche-provides-update-on-Tecentriq-US-indication-for-PD-L1-positive-metastatic-triple-negative-breast-cancer.html
   Google Scholar
• Miles D , GligorovJ, AndréFet al. Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer. Ann. Oncol.32(8), 994–1004 (2021).
   PubMed Web of Science ®Google Scholar
• Borgers JSW , HeimovaaraJH, CardonickEet al. Immunotherapy for cancer treatment during pregnancy. Lancet Oncol.22(12), e550–e561 (2021).
   PubMed Web of Science ®Google Scholar
• Hepner A , NegriniD, HaseEAet al. Cancer during pregnancy: the oncologist overview. World J. Oncol.10(1), 28–34 (2019).
   PubMedGoogle Scholar
• Lee M , SamsteinRM, ValeroC, ChanTA, MorrisLGT. Tumor mutational burden as a predictive biomarker for checkpoint inhibitor immunotherapy. Hum. Vaccin. Immunother.16(1), 112–115 (2020).
   PubMed Web of Science ®Google Scholar
• Klempner SJ , FabrizioD, BaneSet al. Tumor mutational burden as a predictive biomarker for response to immune checkpoint inhibitors: a review of current evidence. Oncologist25(1), e147–e159 (2020).
   PubMed Web of Science ®Google Scholar
• Barroso-Sousa R , JainE, CohenOet al. Prevalence and mutational determinants of high tumor mutation burden in breast cancer. Ann. Oncol.31(3), 387–394 (2020).
   PubMed Web of Science ®Google Scholar
• Angus L , SmidM, WiltingSMet al. The genomic landscape of metastatic breast cancer highlights changes in mutation and signature frequencies. Nat. Genet.51(10), 1450–1458 (2019).
   PubMed Web of Science ®Google Scholar
• Parilla M , RitterhouseLL. Beyond the variants: mutational patterns in next-generation sequencing data for cancer precision medicine. Front. Cell Dev. Biol.8, 370 (2020).
   PubMed Web of Science ®Google Scholar
• Planchard D , PopatS, KerrKet al. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol.29(Suppl. 4), iv192–iv237 (2018).
   PubMed Web of Science ®Google Scholar
• Alva AS , MangatPK, Garrett-MayerEet al. Pembrolizumab in patients with metastatic breast cancer with high tumor mutational burden: results from the targeted agent and profiling utilization registry (TAPUR) study. J. Clin. Oncol.39(22), 2443–2451 (2021).
   PubMed Web of Science ®Google Scholar
• Mosele F , RemonJ, MateoJet al. Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group. Ann. Oncol.31(11), 1491–1505 (2020).
   PubMed Web of Science ®Google Scholar
• Stenzinger A , AllenJD, MaasJet al. Tumor mutational burden standardization initiatives: recommendations for consistent tumor mutational burden assessment in clinical samples to guide immunotherapy treatment decisions. Genes Chromosomes Cancer58(8), 578–588 (2019).
   PubMed Web of Science ®Google Scholar
• Zhang J , ShihDJH, LinS-Y. Role of DNA repair defects in predicting immunotherapy response. Biomark. Res.8(1), 23 (2020).
   PubMed Web of Science ®Google Scholar
• Boyiadzis MM , KirkwoodJM, MarshallJL, PritchardCC, AzadNS, GulleyJL. Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease. J. Immunother. Cancer6(1), 35 (2018).
   PubMedGoogle Scholar
• Lemery S , KeeganP, PazdurR. First FDA approval agnostic of cancer site – when a biomarker defines the indication. N. Engl. J. Med.377(15), 1409–1412 (2017).
   PubMed Web of Science ®Google Scholar
• Andre T , BertonD, CuriglianoGet al. Safety and efficacy of anti–PD-1 antibody dostarlimab in patients (pts) with mismatch repair-deficient (dMMR) solid cancers: results from GARNET study. J. Clin. Oncol.39(Suppl. 3), 9 (2021).
   Web of Science ®Google Scholar
• Sajjadi E , VenetisK, PiciottiRet al. Mismatch repair-deficient hormone receptor-positive breast cancers: biology and pathological characterization. Cancer Cell Int.21(1), 266 (2021).
   PubMed Web of Science ®Google Scholar
• Fusco N , LopezG, CortiCet al. Mismatch repair protein loss as a prognostic and predictive biomarker in breast cancers regardless of microsatellite instability. JNCI Cancer Spectr.2(4), pky056 (2018).
   PubMedGoogle Scholar
• Liberzon A , BirgerC, ThorvaldsdóttirH, GhandiM, MesirovJP, TamayoP. The Molecular Signatures Database (MSigDB) hallmark gene set collection. Cell Syst.1(6), 417–425 (2015).
   PubMed Web of Science ®Google Scholar
• Ribeiro R , CarvalhoMJ, GoncalvesJ, MoreiraJN. Immunotherapy in triple-negative breast cancer: insights into tumor immune landscape and therapeutic opportunities. Front. Mol. Biosci.9, 903065 (2022).
   PubMed Web of Science ®Google Scholar
• Finak G , BertosN, PepinFet al. Stromal gene expression predicts clinical outcome in breast cancer. Nat. Med.14(5), 518–527 (2008).
   PubMed Web of Science ®Google Scholar
• Rose AA , GrossetAA, DongZet al. Glycoprotein nonmetastatic B is an independent prognostic indicator of recurrence and a novel therapeutic target in breast cancer. Clin. Cancer Res.16(7), 2147–2156 (2010).
   PubMed Web of Science ®Google Scholar
• Lee HJ , LeeJJ, SongIHet al. Prognostic and predictive value of NanoString-based immune-related gene signatures in a neoadjuvant setting of triple-negative breast cancer: relationship to tumor-infiltrating lymphocytes. Breast Cancer Res. Treat.151(3), 619–627 (2015).
   PubMed Web of Science ®Google Scholar
• Hendrickx W , SimeoneI, AnjumSet al. Identification of genetic determinants of breast cancer immune phenotypes by integrative genome-scale analysis. Oncoimmunology6(2), e1253654 (2017).
   PubMed Web of Science ®Google Scholar
• Farmer P , BonnefoiH, AnderlePet al. A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer. Nat. Med.15(1), 68–74 (2009).
   PubMed Web of Science ®Google Scholar
• Zheng S , ZouY, XieXet al. Development and validation of a stromal immune phenotype classifier for predicting immune activity and prognosis in triple-negative breast cancer. Int. J. Cancer147(2), 542–553 (2020).
   PubMed Web of Science ®Google Scholar
• Winslow S , LindquistKE, EdsjöA, LarssonC. The expression pattern of matrix-producing tumor stroma is of prognostic importance in breast cancer. BMC Cancer16(1), 841 (2016).
   PubMedGoogle Scholar
• Desmedt C , Haibe-KainsB, WirapatiPet al. Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes. Clin. Cancer Res.14(16), 5158–5165 (2008).
   PubMed Web of Science ®Google Scholar
• Venetis K , CriminiE, SajjadiEet al. HER2 low, ultra-low, and novel complementary biomarkers: expanding the spectrum of HER2 positivity in breast cancer. Front. Mol. Biosci.9, 834651 (2022).
   PubMed Web of Science ®Google Scholar
• Teschendorff AE , MiremadiA, PinderSE, EllisIO, CaldasC. An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer. Genome Biol.8(8), R157 (2007).
   PubMed Web of Science ®Google Scholar
• Rody A , HoltrichU, PusztaiLet al. T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers. Breast Cancer Res.11(2), R15 (2009).
   PubMed Web of Science ®Google Scholar
• Yau C , EssermanL, MooreDH, WaldmanF, SninskyJ, BenzCC. A multigene predictor of metastatic outcome in early stage hormone receptor-negative and triple-negative breast cancer. Breast Cancer Res.12(5), R85 (2010).
   PubMed Web of Science ®Google Scholar
• Yang B , ChouJ, TaoYet al. An assessment of prognostic immunity markers in breast cancer. NPJ Breast Cancer4, 35 (2018).
   PubMed Web of Science ®Google Scholar
• Criscitiello C , BayarMA, CuriglianoGet al. A gene signature to predict high tumor-infiltrating lymphocytes after neoadjuvant chemotherapy and outcome in patients with triple-negative breast cancer. Ann. Oncol.29(1), 162–169 (2018).
   PubMed Web of Science ®Google Scholar
• Walter BA , Gómez-MaciasG, ValeraVA, SobelM, MerinoMJ. miR-21 expression in pregnancy-associated breast cancer: a possible marker of poor prognosis. J. Cancer2, 67–75 (2011).
   PubMed Web of Science ®Google Scholar
• Zhang J , ZhouYJ, YuZHet al. Identification of core genes and clinical roles in pregnancy-associated breast cancer based on integrated analysis of different microarray profile datasets. Biosci. Rep.39(6), (2019).
   Google Scholar
• Zhou Q , SunE, LingLet al. Bioinformatic analysis of computational identified differentially expressed genes in tumor stoma of pregnancy-associated breast cancer. Mol. Med. Rep.16(3), 3345–3350 (2017).
   PubMed Web of Science ®Google Scholar
• Thanmalagan RR , NaoremLD, VenkatesanA. Expression data analysis for the identification of potential biomarker of pregnancy associated breast cancer. Pathol. Oncol. Res.23(3), 537–544 (2017).
   PubMed Web of Science ®Google Scholar
• Harvell DM , KimJ, O’BrienJet al. Genomic signatures of pregnancy-associated breast cancer epithelia and stroma and their regulation by estrogens and progesterone. Horm. Cancer4(3), 140–153 (2013).
   PubMed Web of Science ®Google Scholar
• McCready J , ArendtLM, RudnickJA, KuperwasserC. The contribution of dynamic stromal remodeling during mammary development to breast carcinogenesis. Breast Cancer Res.12(3), 205 (2010).
   PubMed Web of Science ®Google Scholar
• Rønnov-Jessen L , PetersenOW, BissellMJ. Cellular changes involved in conversion of normal to malignant breast: importance of the stromal reaction. Physiol. Rev.76(1), 69–125 (1996).
   PubMed Web of Science ®Google Scholar
• Wang D , PengH, HuY, PiaoX, GaoD, ShaY. Distinctive gene expression patterns in pregnancy-associated breast cancer. Front. Genet.13, 850195 (2022).
   PubMed Web of Science ®Google Scholar
• Tehrani OS . Systemic Treatments in Pregnancy-Associated Breast Cancer. Adv. Exp. Med. Biol.1252, 115–124 (2020).
   PubMed Web of Science ®Google Scholar
• Peccatori FA , LambertiniM, ScarfoneG, DelPup L, Codacci-PisanelliG. Biology, staging, and treatment of breast cancer during pregnancy: reassessing the evidences. Cancer Biol. Med.15(1), 6–13 (2018).
   PubMed Web of Science ®Google Scholar
• Buonomo B , BrunelloA, NoliSet al. Tamoxifen exposure during pregnancy: a systematic review and three more cases. Breast Care (Basel)15(2), 148–156 (2020).
   PubMed Web of Science ®Google Scholar
• Zagouri F , SergentanisTN, ChrysikosD, PapadimitriouCA, DimopoulosMA, BartschR. Trastuzumab administration during pregnancy: a systematic review and meta-analysis. Breast Cancer Res. Treat.137(2), 349–357 (2013).
   PubMed Web of Science ®Google Scholar